BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, May 13, 2024
See today's BioWorld
Home
» Cabrellis' $27.5M Series A To Fund Three SCLC Trials
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cabrellis' $27.5M Series A To Fund Three SCLC Trials
Aug. 8, 2006
By
Karen Carey
No Comments
A Conforma Therapeutics Corp. spinout, barely three months old, closed a $27.5 million Series A financing to cover Phase II trials of its only product, Calsed, to treat small-cell lung cancer. (BioWorld Today)
BioWorld